Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals
NASDAQ | Common Stock
Novan, Inc., a medical dermatology company, focuses on developing and commercializing therapeutic products for skin diseases.
Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases.
The company develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2.
Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation.
The company was incorporated in 2006 and is headquartered in Durham, North Carolina.
On July 17, 2023, Novan, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in theU. S.
Bankruptcy Court for the District of Delaware.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 9, 23 | -0.21 Increased by +54.35% | -0.09 Decreased by -133.33% |
| May 15, 23 | -0.54 Increased by +23.94% | -0.32 Decreased by -68.75% |
| Mar 30, 23 | -0.09 Increased by +79.07% | -0.31 Increased by +70.97% |
| Nov 14, 22 | -0.42 Decreased by -23.53% | -0.39 Decreased by -7.69% |
| Aug 11, 22 | -0.46 Decreased by -2.22% | -0.57 Increased by +19.30% |
| May 16, 22 | -0.71 Decreased by -18.33% | -0.60 Decreased by -18.33% |
| Feb 18, 22 | -0.43 Increased by +28.33% | -0.42 Decreased by -2.38% |
| Nov 10, 21 | -0.34 Increased by +32.00% | -0.42 Increased by +19.05% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 23 | 3.00 M Increased by +58.35% | -14.12 M Decreased by -4.32% | Decreased by -471.26% Increased by +34.12% |
| Dec 31, 22 | 10.47 M Increased by +1.52 K% | 26.58 M Increased by +422.80% | Increased by +253.88% Increased by +119.98% |
| Sep 30, 22 | 5.10 M Increased by +649.56% | -2.44 M Increased by +62.34% | Decreased by -47.91% Increased by +94.98% |
| Jun 30, 22 | 6.15 M Increased by +723.69% | -9.02 M Decreased by -49.69% | Decreased by -146.53% Increased by +81.83% |
| Mar 31, 22 | 1.89 M Increased by +153.28% | -13.53 M Decreased by -51.18% | Decreased by -715.33% Increased by +40.31% |
| Dec 31, 21 | 648.00 K Decreased by -34.15% | -8.23 M Decreased by -24.08% | Decreased by -1.27 K% Decreased by -88.42% |
| Sep 30, 21 | 680.00 K Decreased by -38.18% | -6.48 M Increased by +22.86% | Decreased by -953.53% Decreased by -24.79% |
| Jun 30, 21 | 747.00 K Decreased by -32.09% | -6.02 M Increased by +25.51% | Decreased by -806.29% Decreased by -9.69% |